A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development, LLC
Summary
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants must have been previously diagnosed with histologically confirmed unresectable, locally advanced, or metastatic non-small cell lung cancer, colorectal carcinoma, or head and neck squamous cell carcinoma * Participants with non-small cell lung cancer (NSCLC) adenocarcinoma and colorectal cancer (CRC) must have local molecular testing to determine epidermal growth factor receptor (EGFR) mutational status for NSCLC and Kirsten rat sarcoma/neuroblastoma ras viral oncogene/v-raf murine sarcoma oncogene B1 (KRAS/NRAS/BRAF) mutation status for CRC * Have measurable…
Interventions
- DrugJNJ-95437446
JNJ-95437446 will be administered.
Locations (9)
- Florida Cancer SpecialistsSarasota, Florida
- Tennessee OncologyNashville, Tennessee
- NEXT OncologyFairfax, Virginia
- Severance Hospital Yonsei University Health SystemSeoul
- Samsung Medical CenterSeoul
- Hosp Univ Vall D HebronBarcelona